HeartFlow is the global leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced AI technology.
HeartFlow’s non-invasive personalized cardiac test provides unprecedented visualization of each patient’s coronary arteries, enabling physicians to create more effective treatment plans for their patients.
HeartFlow was founded in 2010 by Christopher K. Zarins and Charles Anthony Taylor. The company is headquartered in Mountain View, California, with offices in Redwood City, Austin, London and Japan.
HeartFlow is the first and only company to provide non-invasive coronary artery anatomy (RoadMap analysis), physiology(HeartFlow® FFRCT), and plaque information (Plaque analysis) based on CCTA. The company has expanded their product portfolio to include anatomic stenosis and plaque information.
HeartFlow's coronary computed tomography angiography (CCTA) and FFRCT have already been recognized by the recent ACC/AHA Chest Pain Guidelines, and HeartFlow’s FFRCT technology is covered by 100% of Medicare and over 98% of commercial payers.
HeartFlow's product is now used in over 725 hospital systems worldwide with over 180,000 patients served to date. HeartFlow's technology has been published in more than 500 peer-reviewed publications that showcase the value of anatomy, physiology, and plaque.
HeartFlow is backed by Bain Capital Life Sciences, Baillie Gifford, Janus Henderson Investors, Wellington Management, Capricorn Investment Group, GE Ventures, Hayfin Capital Management, HealthCor, Martis Capital, USVP and others. The company raised $215M in a Series F round on Apr 06, 2023. This brings HeartFlow's total funding to $792.7M to date. HeartFlow was valued at over $1.5B in a funding raised in Feb 2018.